Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study

F. Cardoso, J. O’Shaughnessy, H. McArthur, P. Schmid, J. Cortes, N. Harbeck, M.L. Telli, D.W. Cescon, P. Fasching, Z. Shao, D. Loirat,Y.H. Park, M. Gonzalez Fernandez, G. Rubovszky,S.A. Im, R. Hui, T. Takano, F. André, H. Yasojima, Z. Liu

European Journal of Cancer（2024）

引用 0|浏览1